Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
RLYB compared with VYNE: revenue, margins and what each company keeps, and the suppliers and customers both name
RLYB
Rallybio Corp
Change
Mkt cap
Revenue
Revenue
VYNE
VYNE Therapeutics Inc.
Change
Mkt cap
Revenue
Revenue
vs
Compare
RLYB
Rallybio Corp
vs
VYNE
VYNE Therapeutics Inc.
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Revenue flow
Desk
News
Calendar
Saved
Search
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Price
Supply-chain overlap
Revenue flow
RLYB: latest quarter is a loss; flow not drawable. VYNE revenue flow unavailable.
Method
›
Price
rebased to 0%
1D
1W
1M
3M
YTD
1Y
5Y
1D
1W
1M
3M
YTD
1Y
5Y
RLYB, solid
VYNE, dashed
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
Only RLYB
9
JNJ
Johnson & Johnson, through its wholly-owned subsidiary, Momenta Pharmaceuticals, Inc. ("J&J")
customer
RXRX
Recursion
customer
SNY
Kymab Limited (Sanofi)
supplier
ABCL
AbCellera Biologics
supplier
5 more · RLYB chain
›
Shared
0
No disclosed counterparties: VYNE.
Only VYNE
0
None
Role chip = supplier or customer
—
= no ticker (unlisted)
Source: SEC EDGAR
RLYB
Rallybio Corp
Change
15.51
· pre 15.51
· delayed
Mkt cap
$83.7M
Revenue
$212,000
Q1 FY26
Revenue
$858,000
FY25
VYNE
VYNE Therapeutics Inc.
Change
20.42
· pre 20.42
· delayed
Pre-market
Oct 30 '26
delayed
Mkt cap
—
Revenue
—
Revenue
—
vs
Compare
Pre-market
Oct 30 '26
delayed
RLYB
Rallybio Corp
vs
VYNE
VYNE Therapeutics Inc.
15.51
pre 15.51
delayed
Price
20.42
pre 20.42
delayed
$83.7M
Mkt cap
—
Q1 FY26
$212,000
Revenue
—
FY25
$858,000
Revenue
—
Change
Change
RLYB
15.51
vs
VYNE
20.42
Pre-market
Oct 30 '26
delayed